PhenoMx, Inc. is a New York digital health company turning ordinary MRI scanners into a 'Personalized Digital Physical Exam.' Its software-first platform applies quantitative imaging and machine learning to non-invasive MRI scans, measuring organs, tissues, body composition, brain, heart and joints over time. Founded in 2017 by Mark Punyanitya and Girish Srinivasan, PhenoMx aims to make precision medicine accessible far beyond the wealthy - from concierge athletes to value-based care and clinical trials worldwide.
Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.
Springbok Analytics is a Charlottesville, Virginia AI company spun out of the University of Virginia that turns standard 2D MRI scans into precise, interactive 3D maps of the musculoskeletal system. Its FDA-cleared platform quantifies up to ~140 individual muscles - measuring volume, fat infiltration, asymmetry, scar tissue, edema and tendon morphology - to create a 'digital muscle twin' used by elite sports teams, clinical researchers, and longevity programs to assess injury risk, track rehab, and monitor age-related muscle change.
Dugal Bain-Kim is the co-founder and CEO of Lifeforce, a clinically integrated health optimization platform he launched in February 2022 with Tony Robbins, Dr. Peter Diamandis and Joel Jackson. An Australian-born finance and healthcare operator who went from BlackRock and Cambridge to telehealth, he built Lifeforce after his own fragmented hunt for answers about his changing body at 38. The company tests 40+ biomarkers via at-home blood draws and pairs the data with clinicians, coaching and supplements, on a stated mission to extend healthy lifespan for five million people by 2030.
Eric Marcotulli is the co-founder and CEO of Elysium Health, a New York consumer health company he started in 2014 to turn academic aging research into products people can actually buy. A former wrestler who became Sequoia Capital's youngest partner before he turned 30, he left venture capital after a business-school case study on cellular aging convinced him that longevity was a solvable engineering problem, not a fairy tale. He built Elysium by recruiting Nobel laureates and a roster of world-class scientists as advisors, raising more than $70 million across several rounds, and selling directly to consumers.
Joe Betts-LaCroix is the co-founder and CEO of Retro Biosciences, a San Francisco longevity biotech on a mission to add 10 healthy years to the human lifespan. A scientist-turned-serial-entrepreneur who once held a Guinness World Record for building the world's smallest Windows PC, he now leads a company backed by OpenAI's Sam Altman, valued at $1.8 billion in 2026, that has run an Alzheimer's clinical trial and co-developed a longevity-focused AI model with OpenAI. He came to biology by an unlikely route: a D-average high schooler who tinkered in shared houses, then earned straight A's, transferred to Harvard, and did research at MIT and Caltech before co-discovering principles of electron transfer in proteins.
Tiny Health is an Austin-based health company that built the first at-home gut microbiome test designed for babies, then extended the same clinically-validated science to children, pregnant people, adults and longevity. It pairs DNA sequencing of stool and vaginal samples with age-specific reference ranges and personalized, research-backed recommendations, aiming to catch early microbiome imbalances linked to eczema, allergies, digestive issues and chronic conditions before they take hold.
Koji Tanabe is the founder and CEO of I Peace, Inc., a Palo Alto and Kyoto biotech building an automated platform to mass-manufacture clinical-grade induced pluripotent stem cells (iPSCs). He earned his PhD in the Kyoto University lab of Nobel laureate Shinya Yamanaka and was a co-author of the landmark paper that first reported the creation of human iPS cells. After postdoctoral work at Stanford, he founded I Peace in 2015 with the goal of giving every person access to their own stem cells for therapy and longevity.
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.
Saad Alam is the co-founder and CEO of Hone Health, a telehealth platform built around preventative, biomarker-driven longevity care. After a year lost inside the conventional healthcare system, he set out to build the clinic he wished he'd found. Hone now counts hundreds of thousands of tested patients and closed a $33M Series A in early 2025, alongside the acquisition of in-home care company ivee. Before Hone, Alam co-founded the edtech company Citelighter and led market research for Eli Lilly's neuroscience franchise.
Gero is a Singapore- and Palo Alto-based biotech company applying physics-informed AI to longitudinal human health data to find the root causes of aging and develop therapies for age-related diseases. Co-founded by physicist Peter Fedichev and entrepreneur Maxim Kholin, Gero has built a foundational model of human health trained on 100M+ medical records, and partners with major pharma including Pfizer and Chugai.
Midi Health is a national virtual care clinic built specifically for women in perimenopause, menopause, and the long midlife stretch that mainstream medicine has historically ignored. Founded by Joanna Strober after her own frustrating search for symptom relief, Midi pairs clinicians trained in menopause medicine with an insurance-covered telehealth platform that treats hot flashes, sleep problems, weight changes, mood swings, and long-term hormone health. Now valued above $1 billion after a $100M Series D in February 2026, Midi serves more than 230,000 patients across all 50 states.
Andrew Lacy is the Founder and CEO of Prenuvo, the company making proactive whole-body MRI scanning a mainstream healthcare tool. A Melbourne-born, Stanford-trained entrepreneur, he previously co-founded Tapulous - the mobile gaming company behind Tap Tap Revenge, acquired by Disney in 2010 - before pivoting to healthcare. At Prenuvo, he has raised $177M in total funding (including a $120M Series B in 2024), grown the company to 110,000+ members across 17 North American clinics, and secured FDA clearance for AI-powered body composition analysis, with plans to expand into Europe and Australia.
Celine Halioua is the founder and CEO of Loyal, a San Francisco biotech company developing the first FDA-approved drug for lifespan extension - starting with dogs. Born in Austin, Texas to a Moroccan mother and German father, she studied neuroscience at UT Austin and nanotechnology at Uppsala University before pursuing a DPhil at Oxford on the health economics of gene therapy. She left Oxford to join Laura Deming's Longevity Fund as Chief of Staff, then founded Loyal in 2019 at age 24. With $250M+ in total funding and the largest clinical trial ever conducted in animal health (1,300+ dogs across 70+ clinics), Loyal's lead drug LOY-002 has cleared FDA safety and efficacy hurdles - putting it on track to become the first longevity drug ever approved for any species.
Maxim (Max) Kholin is the co-founder and COO of Gero, a physics-powered longevity biotech company applying statistical physics and AI to crack the biology of aging. With roots in contract law, international business, and computational drug design, he bridges the gap between cutting-edge science and real-world commercialization. Gero - which he co-founded with physicist Peter Fedichev in 2015 - has pioneered the field of 'Gerophysics,' trained its models on 100M+ longitudinal medical records, and secured partnerships with Pfizer and Chugai Pharmaceutical worth up to $250M in milestones. Based across Singapore and Palo Alto, Kholin's mission is nothing less than transforming humans into a non-aging species.
Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.
Prenuvo runs a chain of clinics built around a 60-minute whole-body MRI designed to spot cancer, aneurysms and hundreds of other conditions before symptoms show up. Founded by Andrew Lacy and radiologist Raj Attariwala, the company is trying to drag American healthcare from reactive to preventive, one scan at a time.
Bryan Johnson is an American tech entrepreneur who built and sold Braintree (the parent of Venmo) to PayPal for $800 million, then funneled the proceeds into venture firm OS Fund and neurotech startup Kernel. He is now best known for Blueprint, a personal protocol and commercial brand built around his 'Don't Die' philosophy, chronicled in the 2025 Netflix documentary 'Don't Die: The Man Who Wants to Live Forever.'
Elad Gil is a Silicon Valley polymath - biologist-turned-Googler-turned-Twitter VP-turned-solo venture capitalist - who has backed 40+ unicorns including Airbnb, Stripe, Coinbase, Pinterest, and OpenAI. Managing $3+ billion as one of the largest solo GPs in venture history, he also co-founded Color Genomics, wrote the 'High Growth Handbook' (published by Stripe Press), and co-hosts the No Priors AI podcast with Sarah Guo. His blog (Elad Blog) reaches tens of thousands of readers on startups, AI, and longevity.
Francisco Leport is the co-founder and CEO of Gordian Biotechnology, a South San Francisco-based company pioneering high-throughput in vivo drug discovery for age-related diseases. Trained as a physicist at Stanford, Leport pivoted from particle physics and energy tech into biotech, driven by a lifelong fascination with longevity sparked by his mother's fruit fly research. Gordian's signature 'mosaic screening' platform uses gene therapy vectors and single-cell RNA sequencing to test hundreds of therapies simultaneously in single animal models, with an AI system called Pythia scoring results against human disease signatures - achieving 80% accuracy in predicting clinical outcomes. The company raised a $60M Series A in April 2024, backed by Founders Fund, Gigafund, and The Longevity Fund, and in early 2026 announced a research collaboration with Pfizer to accelerate obesity drug discovery.
Charles Hoskinson is the founder of Cardano and CEO of Input Output (IOHK), one of the five original co-founders of Ethereum, and a polarizing figure in cryptocurrency who left Ethereum over a for-profit vs. nonprofit dispute. He now runs a peer-reviewed blockchain platform, owns an 11,000-acre buffalo ranch in Wyoming, funds alien-hunting expeditions, donated $20 million to Carnegie Mellon for formal mathematics research, and is pioneering anti-aging medicine while building political influence through his Wyoming Integrity PAC.
Omri Amirav-Drory, Ph.D., is a General Partner at NFX leading NFX Bio, a pre-seed and seed venture fund focused on scientist-founders at the intersection of technology and biology. A former Fulbright Scholar and Stanford postdoc turned biotech entrepreneur, he co-founded Genome Compiler (acquired by Twist Bioscience), launched Tech.Bio, and now backs breakthrough life sciences companies while co-founding Renewal Bio - a longevity company building synthetic embryo-derived tissues to combat aging. His stated mission is ending involuntary death.
Peter H. Diamandis is a Greek-American entrepreneur, physician, and futurist who has founded or co-founded 25+ companies and is best known as the creator of the XPRIZE Foundation - which has launched over $600 million in incentive competitions catalyzing $10+ billion in R&D. A data-driven optimist, he co-founded Singularity University with Ray Kurzweil, runs the Metatrends newsletter (157,000+ subscribers), and is a 4x New York Times bestselling author. His current mission centers on longevity - he launched the $101 million XPRIZE Healthspan in 2024 and published the Longevity Guidebook in January 2025.
Balaji Srinivasan is a serial founder, investor, and author who holds four Stanford degrees and has co-founded companies sold for nearly half a billion dollars. Former General Partner at Andreessen Horowitz and first CTO of Coinbase, he is best known for writing The Network State — a WSJ #2 bestselling book advocating technology-enabled sovereign communities — and for building The Network School, a live experiment in startup-society living on a private island near Singapore.
Kara Swisher is the sharp-tongued conscience of Silicon Valley - a three-decade veteran tech journalist who has interviewed every major figure in tech, co-founded Recode, written the bestselling 'Burn Book' memoir, and hosts the 'Pivot' podcast with Scott Galloway and 'On with Kara Swisher'. Known for her fearless, no-BS style, she's the journalist tech executives fear and secretly want to impress. In 2026, she launched a CNN docuseries exploring the booming longevity industry.